Preimplantation Genetic Testing for Aneuploidy (PGT-A) is a test along with IVF to detect abnormal chromosome numbers or structural abnormalities such as chromosome deletions/duplications in embryos before transfer. Through screening to select chromosomally normal embryos, the chance of miscarriage or fetal chromosomal abnormalities after implantation can be reduced. The success rate of embryo implantation in our partner institutions has increased significantly by 12-15% after using PGT-A screening, showing that our PGT-A test can indeed substantially improve the success rate of IVF.
Non-invasive PGT-A approaches (niPGT-A) have been reported using cell-free DNA (cfDNA) from apoptotic cells detected in spent culture medium (SCM) and shown great promise. Given the nature of niPGT-A to reflect the ploidy state of the whole blastocyst, it is more reliable than trophectoderm biopsy for clinical application.

One-stop service with implementable programs in Taiwan.
Certified by TAF and LDTS (TFDA), the testing quality is guaranteed.